QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights.

Lopez-Medina, Ana I; Campos-Staffico, Alessandra M; Luzum, Jasmine A

Lopez-Medina, Ana I; Campos-Staffico, Alessandra M; Luzum, Jasmine A.

Lopez-Medina AI; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Campos-Staffico AM; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Luzum JA; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

J Cardiovasc Electrophysiol ; 31(10): 2793-2794, 2020 10.

Article in English | MEDLINE | ID: covidwho-738444

Subject(s)

COVID-19; Long QT Syndrome; Azithromycin/adverse effects; Humans; Hydroxychloroquine/adverse effects; Incidence; Long QT Syndrome/chemically induced; Long QT Syndrome/diagnosis; Long QT Syndrome/genetics; Pandemics; Pharmacogenetics; SARS-CoV-2

Keywords

COVID-19; QT prolongation; arrhythmia; azithromycin; hydroxychloroquine; ion channels; pharmacogenetics; polymorphism

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Long QT Syndrome / COVID-19 Type of study: Diagnostic study / Observational study Topics: Long Covid Limits: Humans Language: English Journal: J Cardiovasc Electrophysiol Journal subject: Vascular Diseases / Cardiology / Physiology Year: 2020 Document Type: Article Affiliation country: Jce.14722

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google